Adalimumab induced-inflammatory myopathy in rheumatoid arthritis
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
31/10/2013
31/10/2013
2012
|
Resumo |
The application of immunobiologics for the rheumatoid arthritis treatment may present as a rare complication the development of inflammatory myopathy. Until this moment, there have been described in literature only seven cases of inhibitors of tumor necrosis factor induced-myositis. In this paper, we report the case of the patient with 39 years-old with eight years of arthritis rheumatoid and that due to refractory to various immunosuppressive drugs, the adalimumab was introduced, and evolved to dermatomyositis status. |
Identificador |
ACTA REUMATOLOGICA PORTUGUESA, ALGES, v. 37, n. 2, pp. 180-183, APR-JUN, 2012 0303-464X |
Idioma(s) |
por |
Publicador |
MEDFARMA-EDICOES MEDICAS, LDA ALGES |
Relação |
ACTA REUMATOLOGICA PORTUGUESA |
Direitos |
openAccess Copyright MEDFARMA-EDICOES MEDICAS, LDA |
Palavras-Chave | #ADALIMUMAB #DERMATOMYOSITIS #IMMUNOBIOLOGICS #POLYMYOSITIS #ANTISINTETASE SYNDROME #TRANSFER RNA-SYNTHETASE #DERMATOMYOSITIS #AUTOANTIBODIES #MYOSITIS #POLYMYOSITIS #THERAPY #RHEUMATOLOGY |
Tipo |
article original article publishedVersion |